21st century critical care medicine: An overview

Smitesh Padte, Vikramaditya Samala Venkata, Priyal Mehta, Sawsan Tawfeeq, Rahul Kashyap, Salim Surani

**Abstract**

Critical care medicine in the 21st century has witnessed remarkable advancements that have significantly improved patient outcomes in intensive care units (ICUs). This abstract provides a concise summary of the latest developments in critical care, highlighting key areas of innovation. Recent advancements in critical care include Precision Medicine: Tailoring treatments based on individual patient characteristics, genomics, and biomarkers to enhance the effectiveness of therapies. The objective is to describe the recent advancements in Critical Care Medicine. Telemedicine: The integration of telehealth technologies for remote patient monitoring and consultation, facilitating timely interventions. Artificial intelligence (AI): AI-driven tools for early disease detection, predictive analytics, and treatment optimization, enhancing clinical decision-making. Organ Support: Advanced life support systems, such as Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy provide better organ support. Infection Control: Innovative infection control measures to combat emerging pathogens and reduce healthcare-associated infections. Ventilation Strategies: Precision ventilation modes and lung-protective strategies to minimize ventilator-induced lung injury. Sepsis Management: Early recognition and aggressive management of sepsis with tailored interventions. Patient-Centered Care: A shift towards patient-centered care focusing on psychological and emotional well-being in addition to medical needs. We conducted a thorough literature search on PubMed, EMBASE, and Scopus using our tailored strategy, incorporating keywords such as critical care, telemedicine, and sepsis management. A total of 125...
articles meeting our criteria were included for qualitative synthesis. To ensure reliability, we focused only on articles published in the English language within the last two decades, excluding animal studies, in vitro/molecular studies, and non-original data like editorials, letters, protocols, and conference abstracts. These advancements reflect a dynamic landscape in critical care medicine, where technology, research, and patient-centered approaches converge to improve the quality of care and save lives in ICUs. The future of critical care promises even more innovative solutions to meet the evolving challenges of modern medicine.

**Key Words:** Critical care medicine; Intensive care unit; Precision medicine; Telemedicine; Artificial intelligence; Organ support; Sepsis; Infection control; Patient-centered care

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

### INTRODUCTION

Critical care medicine has been defined by multiple entities. According to the American College of Physicians, it is defined as clinical care consisting of the diagnosis and treatment of a wide variety of clinical problems representing the extremes of human disease[1]. Villar et al[2] defined it as medicine that has the capacity to reverse near-fatal disease states, providing temporary support to the vital organ system while the patient recovers from the underlying disease processes.

Foundations of critical care medicine were laid in the mid-20th century with the initiation of mechanical ventilation, and continuous monitoring of physiological parameters while providing care to the critically ill[3]. Since the advent of the 21st century, there have been significant advancements in this field leading to better outcomes for critically ill patients[4-6]. These advances include better ventilation strategies to prevent lung injury, the initiation of advanced life support systems such as Extra Corporeal Membrane Oxygenation (ECMO), and better management of sepsis syndromes with earlier interventions among others. With the incorporation of technology such as telemedicine into critical care, it has been made possible to provide necessary critical care expertise in rural areas who otherwise would not have access to it. In this ever-evolving landscape, contemporary critical care practitioners are confronted with the formidable task of keeping abreast of the latest advancements and innovations in their field, amidst the vast array of research articles and educational initiatives available. In addition to these challenges and advancements, the integration of artificial intelligence (AI) and the emergence of precision medicine has begun to reshape the intensive care unit (ICU) landscape[7].

Our aim, considering these developments, is to provide a comprehensive overview of progress made in the 21st century in the multidisciplinary field of critical care. By offering concise descriptions of select articles categorized by specific advances, our goal is to provide fundamental insights into the cutting-edge strides made within this domain. Ultimately, we hope to inspire our readers to delve into the original articles for a deeper understanding of the evolving landscape of critical care. The flow diagram of included studies is listed in Figure 1.

### DISCUSSION

#### Precision medicine

The beginning of the 21st century marked the completion of the Human Genome Project in 2003 and ushered in the hope that medical care could be tailored to an individual using their DNA[8]. However, it wasn’t until 2009 that the term “precision medicine” was first coined[9]. This was closely followed by the emergent growth of P medicine – Personalized, Precision, Preventive, Predictive, Pharmacotherapeutic, and Patient Participatory Medicine[10]. The term, broadly...
constructed, describes an approach to disease prevention and treatment that exploits the multiple distinct characteristics of individuals[11]. Despite multiple definitions existing, the Institute of Precision Medicine defined it succinctly “Precision medicine is targeted, individualized care that is tailored to each patient based on his or her specific genetic profile and medical history.” The advances in precision medicine have their roots in oncology but recent developments have seen them make their way into critical care medicine[12].

Genomics and precision medicine go hand in hand as they focus on the individual’s unique heritable characteristics. Recent interest in genomics has gradually increased, with multiple genome-wide association studies and large-scale projects gaining relevance. The International Hap-Map Project, the Precision Medicine Initiative (PMI) in the United States, and the 10000 Genome Project in Great Britain reflect that perhaps the key to precision medicine lies in our genes[11,13].

Recent advances have been hopeful. A retrospective study on 167 trauma patients showed that when a set of 63 genes were incorporated into the genomic score, they appeared to perform better in predicting outcomes than the Injury Severity Score and the Acute Physiology and Chronic Health Evaluation II (APACHE-II) VSV1 metric[14-16]. Gene expression analyses have also been successful in distinguishing the molecularly defined subtypes of sepsis and even estimating their responses to various treatment modalities, such as corticosteroid therapy[11]. Efforts to simplify genetic signatures have led to the identification of an 11-gene signature that can be used to distinguish sepsis from other non-infectious states. Similarly, a two-gene signature was used to classify pediatric infections as either viral or bacterial in origin[11]. A multi-pronged approach to identifying the Single Nucleotide Polymorphisms responsible for the development of acute respiratory distress syndrome (ARDS) from pulmonary or extra-pulmonary causes directed us toward the role of FAAH and the POPDC3 gene[8]. Despite the ever-advancing research, the clinical application of these studies remains uncertain.

Biomarkers in critical care play the all-important role of bringing precision medicine from research papers to the intensive care unit[17]. The value of biomarkers in the ICU lies in their ability to predict the prognosis or even assess the efficacy of a treatment line. There has been much excitement surrounding them, with multiple new biomarkers being studied for the two prototypical ICU Illnesses - ARDS and Sepsis[11].

**Acute respiratory distress syndrome**

Serum markers have shown reasonable success in classifying ARDS based on the etiology (direct vs. indirect lung injury)[11,18]. The ARMA Trial showed that elevated levels of Von Willebrand (VWF) protein, soluble tumor necrosis factor receptors 1 and 2 (sTNFr), plasminogen activator inhibitor-1 (PAI-1) and plasma surfactant protein-D (SP-D) have all been independently associated with worse outcomes in ARDS[19]. A higher baseline plasma soluble receptor for advanced glycation end products was linked to an increased risk of 90-d mortality, according to a meta-analysis of eight studies[19]. Similarly, higher tumor necrosis factor-α and Interleukin 1-β levels in Broncho-Alveolar Lavage Fluid have been
associated with the development of ARDS in at-risk patients[8].

Sepsis

Around 180 biomarkers have been studied in sepsis and septic shock[8]. For the early detection of sepsis, the following five biomarkers were shown to have a sensitivity and specificity of over 90%: Interferon-induced protein (IP)-10, Group II phospholipase (PLA2-II), CD64, and CD11b. PLA2 and CD64 are the only ones that have demonstrated encouraging outcomes in adult patients[8]. In recent years, procalcitonin has also become a biomarker that is increasingly popular in differentiating between bacterial infection and sepsis for better diagnostic accuracy[17]. Additional predictive biomarkers for higher mortality in sepsis include angiopeitoin-1 and angiopeitoin-2, plasma cell-free host DNA, and IL-6 and IL-8[19]. Multi-marker panels are also under investigation, aiming to provide a more comprehensive understanding of complex conditions like sepsis[20-22]. While biomarkers hold great potential, their widespread clinical use still faces challenges and requires further research to fully harness their diagnostic and prognostic capabilities.

Tele-ICU

As per the Centers for Medicare and Medicaid Services, telemedicine is defined as two-way real-time interactive communication between a patient and a physician or practitioner at a distant site through telecommunications equipment that includes audio and visual equipment[23]. Telemedicine is the diagnosis and treatment of patients over long distances using communication technologies[24]. In the critical care setting/Intensive care unit, critical care services offered via telemedicine are known as Tele-ICU or Tele-Critical Care[17]. Even though evidence regarding mortality benefits of 24 x 7 intensivist coverage (both day and nighttime) in the ICU reports mixed results, studies indicate improved mortality rates with high-intensity ICU coverage (mandatory consultation with an intensivist or transfer of care to an intensivist-led team) when compared to low-intensity coverage (optional consultation with the intensivist)[25-27].

Unfortunately, the worsening shortage of intensivists in the United States prevents hospitals nationwide from providing full-time intensivist coverage in the ICU. Tele-ICU has emerged as an alternative model to provide critical intensivist services to hospitals[28-30]. Patients on continuous monitors can be reviewed by remote critical care clinicians, enabling the early identification of emerging health issues[30]. Clinicians can then communicate with on-site care teams to initiate necessary interventions promptly. In addition, the application of tele-critical care has been shown to reduce hospital transfers and improve patient outcomes in sepsis[31].

With the advancement of communicative technologies in the 1970s, early consultative telemedicine critical care services were used unsuccessfully in 1982 by Grundy et al[32]. As technology continued to improve, in 2000 Rosenfeld et al[29] at Johns Hopkins conducted a 16-wk trial of telemedicine on ICU patients and reported improved patient mortality rates. They concluded that telemedicine critical care services can be offered with improved patient outcomes.

Since these studies were done and with the advancement of technological services, Tele-ICU use has grown across the United States. Kahn et al[33] looked at data from the Centers for Medicare and Medicaid Services between 2003-2010, they reported that the number of hospitals using Tele-ICU increased from 16 (0.4% of the total) to 213 (4.6% of the total) and the number of beds covered by telemedicine increased from 598 (0.9%) to 5799 (7.9%).

Over the past two decades, multiple studies have been done looking at outcomes with Tele-ICU. Even though initial studies looking at a few hundred patients showed mixed results in terms of mortality, recent multiple larger studies indicate improved outcomes including ICU mortality and length of stay. A meta-analysis done by Young et al[34] in 2011 and Chen et al[35] in 2017 that looked at 41374 and 192265 patients respectively showed improved ICU mortality and length of stay with Tele-ICU. Similarly, a review done by Mackintosh showed improved patient mortality with Tele-ICU[36].

The major barrier with Tele-ICU is the costs ($50000-$100000 per bed) and the worsening shortage of intensivists in the United States prevents hospitals nationwide from providing full-time intensivist coverage in the ICU. Tele-ICU has emerged as an alternative model to provide critical intensivist services to hospitals around the country.

AI

AI constitutes the set of algorithms that enable machines to reason and execute tasks that include problem-solving, object and word recognition, state inference, and decision-making[38]. It expands upon Machine Learning via Artificial Neural Networks by utilizing tensors for “Deep Learning” (DL). As opposed to a sole clinician, DL can efficiently process multiple inputs, programming complex non-linear relationships to generate individualized prediction models[39]. In 1981, logistic regression was applied to validate the APACHE score, signifying the first use of AI in critical care medicine to support clinical decisions[40].

Featuring two super learner prediction models, SL1 and SL2, Pirracchio et al[41] introduced a novel mortality prediction algorithm for ICU patients in 2015. Compared to the Sequential Organ Failure Assessment (SOFA) and Simplified Acute Physiology Score II (SAPS II) scores, it displayed greater efficacy in predicting early mortality[42]. In addition, the United States Food and Drug Administration has authorized the clinical application of certain healthcare products, such as image analysis software (e.g., DeepRhythmAI[43] by Medicalgorithmics SA) and basic cardiopulmonary function monitoring software (e.g., IRNF App by Apple Inc. and Air Next by NuvoAir AB)[40]. Jiao et al[44] developed an AI system for predicting the prognosis of coronavirus disease 2019 (COVID-19) patients based on chest X-rays. The model exhibited significantly better prognostic performance compared to conventional severity scores in both internal and external testing. AI-based tools for rapid COVID-19 diagnostics have been developed, including those by Mount Sinai Health System and the University of Minnesota, in collaboration with Epic Systems and M Health Fairview[45]. Software predictors, like COViage[46] and the CLEWICU System[47], identify high-risk patients for clinical events such as intubation, respiratory failure, and low blood pressure. Additionally, adherence to AI-specific reporting guidelines like SPIRIT-AI[48], CONSORT-AI, and HUMANE can enhance AI application development and quality[49].
AI-guided tools for sepsis have shown promise as well. Earlier detection via sepsis surveillance algorithm has been a pioneering advancement in the 21st century[50]. Automation of sepsis clinical data abstraction via computable phenotype is crucial in sepsis care and research[51]. A reinforcement learning model improved mortality when clinical decisions aligned with the model’s suggestions[52]. Predicting changes in urine output after fluid administration, an essential end-organ perfusion indicator, achieved an area under the curve of 0.86 using a gradient-boosting algorithm[52,53]. AI-guided POCUS can even enhance inter-operator reliability[54]. Machine learning holds the potential for enhancing sepsis management and volume responsiveness prediction in the ICU in this new century.

In a complex ICU setting with challenging staff and resource management, AI can enhance disease prognostication for informed decision-making[45]. Elhazmi et al.[55] utilized a decision tree to predict COVID-19 patients’ 28-d ICU mortality. It proved useful for identifying individuals at high risk. Leveraging a cohort of 289551 COVID-19 patients, Lazzarini et al.[56] introduced the ‘Gradient Boosting Decision Tree’ machine learning model that predicts severe COVID-19 cases, demonstrating its superior performance compared to older models and even human experts in terms of precision and recall.

Language learning models like Chat-GPT/GPT-4 have the potential to assist clinical judgment under intensivist supervision, improving clinical decision support optimization, as well as in clinical research in critical care[57]. Its applications extend to ECMO management, education, weaving, and decision-making[57]. Furthermore, it could be applied to other commonly used ICU medical equipment such as ventilators, defibrillators, electrocardiograms, or critical care radiology workflow[58]. While the model displays a capacity to learn and adapt, it has certain limitations in terms of medical expertise[45].

Challenges in applying machine learning (ML) in intensive care include poor data quality, ethical and legal concerns, and the absence of specific educational programs[59]. Most ML algorithms lack external validation, and real-world performance issues, like the EPIC sepsis-alleviation system, highlight practical hurdles. A vast majority of ML studies in intensive care are retrospective, with limited evaluation in clinical practice[45]. Inclusive datasets are crucial for AI model applicability, but transparency and legal guidelines are vital for trust and accountability[52]. Despite challenges, AI is poised to grow in its role in critical care in the future.

Organ support

Extra corporal membrane oxygenation: The ECMO is a device that temporarily replaces the heart and lung function via gas exchange through an extracorporeal circuit, while the patient is being resuscitated from underlying cardiopulmonary pathology[60]. In addition to providing respiratory and circulatory support, one of the main goals of ECMO is to prevent ventilator-induced lung injury which is a major cause of mortality in this population[61]. This feature of ECMO is thought to be more important in improving outcomes than providing oxygenation support[60,61]. ECMO technology was developed in the 1960s and used on humans for the first time in the 1970s[62,63]. Due to the advancement of technology, new extracorporeal circuit design, and better ventilation strategies, observational studies started reporting promising results in terms of survival outcomes[64,65]. In 2009 multicenter randomized controlled trial (RCT) done by Peek et al.[64] reported improved outcomes with ECMO compared to conventional management. Even though the results of the Conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR) trial[66] were controversial, these studies led to renowned interest in ECMO. This along with continuing development in technology led to an increase in the use of ECMO worldwide[67,68]. As of 2015, more than 78000 cases have been reported to the Extracorporeal Life Support Organization (ELSO) and the number of hospitals reporting to ELSO has been steadily rising[68]. Meta-analysis of RCT done by Munshi et al.[69] in 2019 published in the Lancet showed reduced 60-d mortality when compared to mechanical ventilation. With recent studies showing strong evidence in favor of ECMO, even after cardiopulmonary resuscitation and with ongoing advances in technology ECMO will likely be the standard of care in the future, if not already for ICU patients who meet the ECMO support initiation criteria[70].

Continuous renal replacement therapy

Dialysis, an external machine that can serve as renal replacement therapy, was initially conceptualized in 1854 by Thomas Graham and was first used in patients in 1945 by Dr. William Koff. Since then with advances in technology and techniques, dialysis has become the standard of care for renal replacement in patients with renal failure[71]. Traditional dialysis is performed intermittently, typically a few days a week. In 1977 Peter Kramer performed the first continuous arteriovenous hemofiltration (CAVH), with the main advantage being hemodynamic stability even in critically ill patients (SVSV)[72,73]. With technological advancements, CAVH has paved the way for development of present-day continuous veno-venous hemofiltration (CVVH).

In addition, over a 48-h period CVVH leads to a higher net fluid removal compared to regular dialysis, so it has shown to be beneficial in critically ill patients requiring large-volume fluid resuscitation[74]. Another advantage of CVVH would be in patients with cerebral edema, ischemic heart disease (IHD) may lead to hypotension and consequent compensatory cerebral vasodilation. Also, the rapid removal of urea with IHD can lead to water shifting into the cellular space[74,75]. Despite the ambiguity of survival benefit with CVVH compared to IHD. There are clear advantages with CVVH compared to IHD in specific critically ill patients and it's been used widely in intensive care units since the beginning of the 21st century.

Infection control

In the ICU, 19.2% of patients develop infections, compared to 5.2% in other hospital wards[76]. On any given day, about one in 31 hospital patients has at least one healthcare-associated infection[77]. Mucosal disruption, immune suppression,
invasive devices, surgery, antibiotic use, and encounters with multidrug-resistant pathogens are all contributing factors. Effective prevention measures including universal gloving, gowns, masks, and hand hygiene have been used since the inception of critical care, but they can be time-consuming[78]. Electronic monitoring tools for hand hygiene, like Electronic Hand Hygiene Monitoring Systems (EHHMS), are increasingly used to capture and promote compliance in the 21st century[79]. While direct observation is the gold standard, EHHMS offers larger and less biased data sets, reducing the Hawthorne effect and providing a more comprehensive view of compliance[80].

In the past two decades, healthcare worker (HCW) vaccination against nosocomial infections has gained prominence [79]. Since July 2007, the Joint Commission has mandated annual influenza vaccination programs in healthcare facilities. Pertussis vaccination for HCWs was recommended due to the rising incidence. Similarly, COVID-19 vaccines became mandatory to curb the pandemic since the year 2020[81]. Biocontainment facilities have become essential for managing infectious diseases like the Ebola virus while minimizing transmission risks in the 21st century[82].

Viana Martins et al[83] made a crucial development in the COVID-19 fight by highlighting the efficacy of UV-C devices in inactivating the airborne severe acute respiratory syndrome coronavirus. The BETR Disinfection Study[84] from 2016 influenced healthcare facilities to adopt UV-C as a standard method for multidrug-resistant infections. However, Rock et al[85] found UV-C disinfection did not reduce certain infections in immunocompromised patients. Nonetheless, UV-C disinfection remains crucial in preventing other healthcare-associated infections. Novel technologies that enhance environmental decontamination, like hydrogen peroxide vapor, ultraviolet light, self-disinfecting surfaces, antimicrobial textiles, and sporidical disinfectants, effectively combat contamination and minimize infection risks in the 21st century and are expected to advance further[79].

With the increasing use of electronic health record systems in the past two decades, electronic orders and reminders have become essential tools for curbing Catheter-Associated Urinary Tract Infections[80]. They prompt appropriate urinary catheter use and prompt removal, significantly reducing infection rates. Decision-support tools, such as electronic nudges and hard stops, steer clinicians away from choices that may heighten HAI risk. These tools are invaluable in the era of rapid infectious disease spread.

Digital polymerase chain reaction has emerged as a promising diagnostic technology in the past 20 years. It aids in the early identification of microbial genes, quantifies microbial burden, and explores host responses, making it a valuable tool in diagnosing and differentiating conditions like sepsis from systemic inflammatory response syndrome (SIRS[86]). Moreover, predictive modeling using machine learning is revolutionizing infection prevention. Recent studies demonstrate its potential in assessing patients’ risk of central line-associated bloodstream infections, ventilator-associated pneumonia, C. difficile infections, and catheter-associated urinary tract infections. Some models outperform traditional regression methods[79]. More testing and validation are underway to incorporate these new advances into practice.

**Ventilation strategies**
Mechanical ventilation (MV) is a lifesaving intervention that provides temporary oxygenation and ventilation for patients with respiratory failure until the underlying pathology is treated. It consists of invasive and non-invasive MV. Invasive MV consists of an endotracheal tube placed in the patient’s trachea through the mouth or nose. This tube is connected to a ventilator which delivers a set amount of oxygen and a number of breaths per minute[87]. Non-invasive ventilation (NIV) consists of a machine that delivers a set amount of oxygen and ventilatory breaths via an external mask[87].

**Invasive mechanical ventilation**
The 21st-century ventilators have the option of various ventilation modes[88]. Volume limited, Pressure Limited, and Pressure Support (PSV) are the three main modes of ventilation. In volume limited, inspiration ends after a set inspiratory volume, in pressure limited inspiration ends after a set inspiratory pressure. Each mode has its advantages and can be used in specific patient situations. With PSV ventilation mode, once a breath is triggered by the patient, inspiratory pressure is delivered until the inspiratory flow decreases to a predetermined percentage of its peak value.

**Ventilation in ARDS**
Enhancing ventilation strategies for ARDS patients is one of the more significant advances in the field of critical care over the past two decades and it has led to improved patient outcomes. The landmark ARDSnet trial in 2000 demonstrated that lower tidal volume ventilation (6 mL/kg) in ARDS patients leads to lower mortality and an increased number of days without ventilator use[89]. This was subsequently supported by multiple studies which reported similar results[90-92].

As of the year 2023, low tidal volume ventilation (LTV) should be the standard of care for ARDS patients around the world. Despite the existing evidence, studies suggest that low tidal volume ventilation in ARDS patients is underutilized. In a multicenter observational study of ARDS patients around the United States showed that LTV was utilized in only 30% of the cases. Awareness needs to be raised and there needs to be a standardized institutional protocol to improve compliance with LTV[92].

**Non-invasive ventilation**
Numerous studies conducted at the onset of the 21st century have confirmed the efficacy of NIV in COPD exacerbation[93, 94]. As per the latest American Thoracic Society/European Respiratory Journal guidelines in the year 2017, NIV is indicated in specific patients with acute respiratory failure secondary to COPD exacerbation and cardiogenic pulmonary edema[95].
Sepsis management

Sepsis, a life-threatening organ dysfunction from an infection-triggered host response, presents a rising global challenge. Incidence has steadily increased since 1991, causing about 49 million sepsis cases and 11 million deaths in 2017[96]. Despite therapeutic progress, septic patients face high in-hospital mortality, comprising 20% of all global deaths. The Surviving Sepsis Campaign (SSC) started at the dawn of 21st century in the year 2003, uniting medical societies across the globe to create guidelines for reducing sepsis mortality[97]. Conventional therapies center on fluids, source control, and antimicrobials. With the initiation of Surviving Sepsis Campaign, indicators like central venous pressure and central venous oxygen saturation were added to the definition to help with the diagnosis[97,98]. These guidelines have been continuously updated, with the latest in 2021[99]. The evolving care bundles with shorter time frames (from 3-6-h bundles to 1-h bundles) for sepsis, emphasizing rapid recognition and resuscitation, place emergency physicians in a critical role[98,100]. The third re-definition in 2016 was done to improve the specificity of the old definition of Sepsis[101]. In this latest definition terms like SIRS, Severe Sepsis were removed. Sepsis-related quick SOFA (qSOFA) was introduced[102] as per the latest update. Screening tools like SIRS, MEWS, NEWS, and qSOFA help identify septic patients[103]. Below are the main advances in various aspects of sepsis management over the past two decades.

Antimicrobials

Since 2004, sepsis management guidelines recommended the initiation of antibiotic therapy within one hour of the presentation of patients with severe sepsis and septic shock in the ICU[104]. Multiple large studies have demonstrated increased mortality with each hour of delay in antibiotic administration in this population[105,106].

As per the latest SSC guidelines, in patients with sepsis or septic shock therapy initiation covering all likely pathogens and antibiotic coverage, once the pathogen is identified has been a cornerstone management in this century[102]. In the current standard of care, most patients with sepsis shock receive anti-pseudomonal antibiotic coverage[107] as part of empiric antibiotic therapy[100].

Intravenous fluid

Based on Rivers et al[108], SSC had initially recommended fluid bolus administration as an integral component of sepsis management[104,108]. After this over the past two decades, multiple large trials[109-112] and studies have shown variable results in outcomes between EGDT and usual therapy. Taking all the existing evidence into consideration, SSC guidelines currently recommend 30 mL/kg bolus as part of resuscitation from sepsis-induced hypoperfusion.

Even though guidelines do not recommend a specific type of intravenous fluid in sepsis, evidence indicates improved mortality with the use of balanced crystalloids such as lactated ringer, and plasmalyte compared to normal saline[113]. Additionally, albumin inclusion during resuscitation has no impact on sepsis or septic shock mortality[114].

Experimental therapies

Innovative approaches in the 21st century target immune balance through extracorporeal therapies (ECT) or blood purification for sepsis care[115]. ECT aims to reduce inflammatory mediators and toxins, achieving immune balance and homeostasis. Removing peak cytokine levels in early sepsis, per the ‘cytokine peak concentration’ hypothesis, can limit organ damage and multi-organ dysfunction syndrome. ECT methods include convection therapies (CRRT, HVHF, HCO), adsorption therapies (e.g., Polymixin B, CytoSorb®), and combination therapies[115]. The Molecular Adsorbent Recirculating System (MARS®,) supports the liver by removing albumin-bound toxins, showing short-term benefits in hepatorenal syndrome and hepatic encephalopathy[116]. "Externally modulated electric-based devices" sense and target endotoxins with antibiotics to curb inflammation[117]. A lipopolysaccharide (LPS) neutralizing cartridge detects and neutralizes LPS, combining antibiotic and anti-inflammatory effects.

Recent advances in critical care technology have introduced hemodynamic monitoring tools like pulse contour analysis, which calculates cardiac output from arterial line data. Various invasive and noninvasive markers, including end-tidal CO2, inferior vena cava collapsibility index, and point-of-care ultrasound (POCUS), are evaluated for sepsis[118]. POCUS offers rapid LV and RV function assessments, even remotely. Venous Doppler waveform analysis and the venous excess ultrasound score help predict venous congestion severity. However, POCUS alone can’t replace a comprehensive cardiovascular assessment. It is being considered alongside clinical parameters.

Recently, nanomaterial strategies have offered a more versatile tool for sepsis management. They serve as inherent therapeutics or nanocarriers for precise agent delivery. These formulations possess antibacterial, anti-inflammatory, immunomodulatory, and anti-oxidative effects, providing a multifunctional treatment against sepsis[119]. Cell membrane-derived biomimetic nanoplatorms trap and neutralize toxins. Nano-delivery systems customize agent kinetics and enhance targeted distribution, reducing peripheral exposure and toxicity[120]. Clinical trials for sepsis treatment include amikacin-loaded lipid nanocrystals, Resatorvird emulsion, Pegylated filgrastim, Spi-Argent®, Arikeyce®, and more[117]. Figure 2 outlines the various applications of nanoparticle technology in sepsis management[120].

Patient centered care

Several innovations have occurred in the 21st century towards a more patient-centered approach in ICU care, emphasizing communication, engagement, and individualized support for both patients and their families[121]. The primary focus is on ‘Family-centered rounds’, which involve including family members in daily rounds. It has enhanced communication, transparency, and shared decision-making between healthcare providers and the patient’s family, fostering a collaborative care approach and improving outcomes[122]. Secondly, the ‘Tele-ICU services’ enable timely interventions, facilitate communication with off-site specialists, and provide an additional layer of support, particularly in...
Figure 2 Applications of nanotechnology and nanoparticles in sepsis management (adapted from Zhou et al[120]).

underserved or rural areas or resource-limited countries[123].

Thirdly, the use of ‘Patient and family education technologies’ has empowered patients and their families with information about medical conditions, treatment options, and post-discharge care, promoting a more informed and engaged healthcare experience[124]. Additionally, ‘Virtual visitation programs’ have addressed challenges related to physical visitation, particularly during the COVID-19 pandemic, by allowing patients to connect with their loved ones virtually, positively influencing emotional well-being. Lastly, the ‘Patient-controlled comfort measures’ have integration of customizable environmental and comfort controls. This allows patients to personalize their immediate surroundings, influencing factors like lighting and noise levels, contributing to a more comfortable and healing-oriented environment including pain and sedation control[125].

CONCLUSION

In conclusion, the landscape of critical care medicine in the 21st century has been marked by remarkable advancements, underscoring a commitment to enhancing patient outcomes in ICUs. The summarized developments, ranging from precision medicine and telemedicine to AI and advanced life support systems, showcase the dynamic evolution of critical care practices. These innovations not only demonstrate a keen focus on individualized patient care but also reflect a broader integration of technology and research into clinical decision-making processes. The emphasis on infection control, ventilation strategies, and sepsis management underscores a commitment to combating emerging challenges in critical care.

Furthermore, the transformative shift towards patient-centered care highlights a holistic approach, recognizing the importance of addressing not only the medical needs but also the psychological and emotional well-being of patients. As the field continues to evolve, the promise of even more innovative solutions is on the horizon, poised to meet the complex and ever-evolving challenges of modern medicine in the critical care setting. These advancements collectively contribute to a future where the synergy of technology, research, and patient-centered approaches not only improves the quality of care but also saves lives in ICUs.

FOOTNOTES

Author contributions: Padte S, Kashyap R, and Surani S contributed to the study conceptualization and methodology; all co-authors contributed to data acquisition; the original draft was prepared by Padte S, Venkata VS, Mehta P, Tawfeeq S, and Kashyap R, and Surani S have supervised and final edited the manuscript; All listed co-authors authors provided intellectual contributions and made critical revisions to this paper; All authors approved the final version of the manuscript.

Conflict-of-interest statement: None of the authors have any conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.
It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Corresponding Author's Membership in Professional Societies:** Society of Critical Care Medicine.

**S-Editor:** Liu JH

**L-Editor:** A

**P-Editor:** Zheng XM

**REFERENCES**


